134.28
Abbott Laboratories 주식(ABT)의 최신 뉴스
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock - MSN
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories Q2 Earnings: Dividends Don’t Lie (NYSE:ABT) - Seeking Alpha
Do New Glucose Monitoring Launches Signal Sustainable Profit Growth for Abbott (ABT)? - simplywall.st
Abbott Laboratories shares rise 1.11% intraday as Senseonics Holdings, Inc. reports Q2 revenue up 37%. - AInvest
Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters - Reuters
Abbott launches next-gen MitraClip, TriClip G5 systems - MassDevice
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Abbott Laboratories' Earnings Raise Concerns Despite Strong Profit Numbers - AInvest
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It? - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) Earnings Are Of Questionable Quality - Yahoo Finance
Arterial Stents Market Surge to 2035: Growth Driven by Abbott, Boston Scientific, BIOTRONIK & Biosensors - openPR.com
Medical Devices & SuppliesDiversified Stocks Q2 Highlights: Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Is a Favorite Amongst Institutional Investors Who Own 80% - 富途牛牛
What institutional investors are buying Abbott Laboratories stockOutstanding trading profits - Jammu Links News
What is the dividend policy of Abbott Laboratories stockFree Stock Chart Pattern Guide - Jammu Links News
Is it the right time to buy Abbott Laboratories stockTremendous wealth creation - Jammu Links News
How does Abbott Laboratories compare to its industry peersMaximize portfolio growth with professional advice - Jammu Links News
Abbott Laboratories Stock Analysis and ForecastCapitalize on momentum-driven opportunities - Jammu Links News
When is Abbott Laboratories stock expected to show significant growthConsistent high-performance stocks - jammulinksnews.com
UBS Shrugs Abbott Laboratories’ (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating - MSN
RECKITT (RBGLY) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Reckitt Benckiser Group plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations - simplywall.st
Stock Analysis | Abbott Laboratories OutlookMixed Signals Amid Strong Fundamentals and Technical Uncertainty - AInvest
Similac NEC Lawsuit: 2025 Updates & List of Affected Formulas - Drugwatch.com
What makes Abbott Laboratories stock price move sharplyPotential Breakout Stock List Published This Week - metal.it
Abbott Laboratories Shares Drop 1.84 as Analysts Clash on Value Amid $850M Volume 155th in Market Activity - AInvest
How volatile is Abbott Laboratories stock compared to the marketMarket Forecast Signals For Fast Growth - Jammu Links News
Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Why Abbott Laboratories (ABT) Remains a Buy Despite Diagnostic Segment Weakness - AInvest
Abbott Laboratories 2025 Q2 Earnings Strong Performance as Net Income Climbs 36.6% - AInvest
Biotechnology Market is evolving rapidly Through 2025 To 2032 | Abbott Laboratories, Amgen Inc., GlaxoSmithKline - openPR.com
Abbott Gains 1.31% Amid 140th Trading Volume Rank as Analysts Weigh Diagnostic Sector Growth and Competitive Risks - AInvest
Meal Replacement Market Is Booming Worldwide 2025-2032 | Abbott - openPR.com
Paul MacDonald's Top Picks: Stryker, Abbott Labs & Elevance Health - BNN Bloomberg
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche - Yahoo Finance
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT) - MSN
2nd Abbott Baby Formula Bellwether Falls Before Trial - Law360
Does Abbott Laboratories stock perform well during market downturnsBuild a winning investment strategy today - jammulinksnews.com
Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating - Insider Monkey
Abbott Laboratories' Q2 Earnings Report Presents Mixed Picture, Leerink Partners Decreases PT to $136, Maintains Hold Rating - AInvest
RBC Capital Bullish on Abbott Laboratories, Raises Price Target to $147. - AInvest
How does Abbott Laboratories generate profit in a changing economyMaximize your returns with portfolio optimization - jammulinksnews.com
자본화:
|
볼륨(24시간):